Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 28, 2024; 30(32): 3726-3729
Published online Aug 28, 2024. doi: 10.3748/wjg.v30.i32.3726
Evaluating the efficacy of immunotherapy in gastric cancer: Insights from immune checkpoint inhibitors
Yu-Nuo Yang, Li-Sheng Wang, Yan-Qi Dang, Guang Ji
Yu-Nuo Yang, Yan-Qi Dang, Guang Ji, Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
Li-Sheng Wang, Department of Biochemistry, University of Ottawa, Ottawa K1H 8M5, ON, Canada
Co-corresponding authors: Yan-Qi Dang and Guang Ji.
Author contributions: Ji G and Dang YQ designed research; Yang YN and Wang LS wrote the paper. We have designated two corresponding authors for this paper to leverage their complementary expertise and ensure comprehensive guidance throughout the research process. Dang YQ possesses profound knowledge in diseases of the digestive system, bringing valuable insights into the theoretical framework and methodology. Ji G, on the other hand, provides a deep understanding of theoretical frameworks and has been instrumental in interpreting our results within the broader context of the field. Their combined efforts have been instrumental in shaping the study's direction and ensuring its scientific rigor. By having both as corresponding authors, we aim to facilitate effective communication and collaboration, ensuring the highest quality and impact of our research.
Supported by National Nature Science Foundation of China, No. 82320108022; Shanghai Rising-Star Program, No. 21QA1409000; and Shanghai Frontier Research Base of Disease and Syndrome Biology of Inflammatory Cancer Transformation, No. 2021KJ03-12.
Conflict-of-interest statement: All the authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guang Ji, MD, PhD, Professor, Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, No. 725 South Wanping Road, Xuhui District, Shanghai 200032, China. jiliver@vip.sina.com
Received: February 28, 2024
Revised: August 6, 2024
Accepted: August 9, 2024
Published online: August 28, 2024
Processing time: 180 Days and 20.7 Hours
Core Tip

Core Tip: This study delved into the determinants influencing the efficacy of immune checkpoint inhibitor (ICI) therapy in gastric cancer. Employing COX regression analysis, it crafted a prediction model aimed at enhancing the efficiency and simplicity of evaluating the suitability of immunotherapy. These findings offer novel perspectives for the judicious utilization of ICIs, contributing to improved treatment decision-making and patient care.